
John L. Hays, MD, PhD, discusses the evolution of the treatment paradigm for patients with metastatic colorectal cancer who experience disease progression following standard chemotherapy regimens.

Your AI-Trained Oncology Knowledge Connection!


John L. Hays, MD, PhD, discusses the evolution of the treatment paradigm for patients with metastatic colorectal cancer who experience disease progression following standard chemotherapy regimens.

John L. Hays, MD, PhD, discusses the significance of the approval for tucatinib and trastuzumab for patients with HER2-expressing metastatic colorectal cancer.

John L. Hays, MD, PhD, discusses the evolution of treating patients with hepatocellular carcinoma.

John Hays, MD, PhD, discusses immunotherapy research in gynecologic cancer.

John Hays, MD, PhD, discusses the progression of immunotherapy in treating patients with ovarian cancer.

John Hays, MD, PhD, discusses investigational combinations of PARP inhibitors and immunotherapy in ovarian cancer.

John Hays, MD, PhD, discusses the potential for PARP inhibitor combinations in patients with ovarian cancer.

Published: December 11th 2019 | Updated:

Published: December 16th 2019 | Updated:

Published: January 15th 2020 | Updated:

Published: February 22nd 2020 | Updated: